Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals


 

Melt Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021

Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, today announced that Harrow Health has provided a $13.5 million senior secured loan to Melt Pharmaceuticals.

Melt Pharmaceuticals plans to use the proceeds to conduct its pivotal Phase 2 efficacy study for the company's lead drug candidate, MELT-300, a patented combination of midazolam and ketamine in a rapidly dissolving, sublingual tablet to provide sedation and analgesia for patients undergoing cataract surgery. Melt's IV-free and non-opioid approach seeks to replace the current practice of IV-delivered sedation and analgesia medication, including the use of fentanyl intraoperatively and other opioids prescribed for pain post-operatively. Melt expects to dose its first patient in September 2021 and to report topline clinical results in the spring of 2022. Pending the outcome of the Phase 2 clinical study, Melt Pharmaceuticals anticipates beginning a Phase 3 clinical study, which compares MELT-300 to a placebo, in the second half of 2022. Melt also expects to file with the U.S. Food and Drug Administration (FDA) two investigational new drug applications (INDs) for its MELT-210 and MELT-400 programs in the latter part of 2021.

"We are pleased to have secured this non-dilutive funding that allows us to complete our Phase 2 clinical study of MELT-300 and execute our overall clinical strategy, which we expect to generate data to ultimately support a new drug application (NDA) submission to the FDA," said Larry Dillaha, M.D., CEO of Melt Pharmaceuticals. "Recent estimates are that as many as 50% of the over four million annual cataract surgeries in the U.S. involve patients being exposed to opioids perioperatively. If FDA approved, MELT-300 will be a new surgical protocol that should virtually eliminate opioid exposure during cataract surgery, ameliorating, in part, the devastating public health effects of the U.S. opioid crisis. As a result of this funding, we will now also be able to advance our goal of leveraging our patented technology in other short-duration procedures in medical fields such as pediatrics, dermatology, plastics, and women's health."

Mark L. Baum, Harrow Health CEO, added, "As Melt Pharmaceuticals' largest shareholder, an owner of royalty rights of potential MELT-300 sales, and given our domain expertise in commercializing ophthalmic surgical pharmaceutical products, Harrow is delighted to provide the capital for Melt's flagship MELT-300 program and to advance other valuable Melt development programs. Dr. Dillaha has an impressive 505(b)(2) drug approval track record, and we believe strongly in his team's strategy with the MELT-300 program. For Harrow, I can think of few near-term events that could deliver the magnitude of value as MELT-300, a multi-patented drug development candidate with a billion-dollar annual revenue opportunity in the growing ophthalmic surgery market. I am very excited about what this potential paradigm shift away from opioids and IVs could mean clinically for patients and ophthalmologists and financially for Harrow shareholders."

The senior secured loan, funded with approximately $12.5 million of new cash and about $1 million of existing amounts owed to Harrow Health, has a one-year term with no principal payments due until maturity and no pre-payment penalties. The loan carries an annual interest rate of 12.5%, which can be paid-in-kind in the form of additional principal balance. The loan is secured against nearly all of Melt's assets, including all patents issued in the U.S., Australia, Japan and South Korea related to Melt's platform technologies. Concurrent with entering into the loan agreement, Harrow Health was also provided a five-year, right-of-first-refusal option related to third-party commercialization rights of Melt's drug candidates.

Harrow Health owns approximately 44% of the equity interests in Melt Pharmaceuticals along with a 5% royalty right on sales of MELT-300.

Share:

 

Email Print

 

More Grand Rounds:

 

Ascension Saint Thomas Rutherford to Invest in Facility Development

Ascension Saint Thomas Rutherford to Invest in Facility Development

Hospital Preparing for Higher Acuity Services

Read More

IVX Health Secures $100 Million Growth Investment from Great Hill Partners to Accelerate New Market Expansion

(BUSINESS WIRE)--IVX Health, a national provider of outpatient infusion centers, announced today the completion of a $100 million Series F minority investment from Great Hill Partners, a private equity firm that invests in high-growth, disruptive companies.

Read More

HCA Healthcare Agrees to Purchase Five Utah Hospitals from Steward Health Care

HCA Healthcare, Inc. (NYSE:HCA) and Steward Health Care announced the signing of a definitive agreement for HCA Healthcare to acquire the operations of Steward Health Care's five Utah hospitals.

Read More

KIMBERLY WELLS APPOINTED CEO OF PINEWOOD SPRINGS

KIMBERLY WELLS APPOINTED CEO OF PINEWOOD SPRINGS

Kimberly Wells has been appointed Chief Executive Officer (CEO) of Pinewood Springs in Columbia, Tenn., effective September 27, 2021. Wells currently serves as the Vice President of Operations for TriStar Horizon Medical Center in Dickson, Tenn.

Read More

NEW AHA ANALYSIS: TAX-EXEMPT HOSPITALS PROVIDED $105 BILLION IN TOTAL BENEFITS TO THEIR COMMUNITIES

Total Community Benefits Were 13.9% of Total Hospital Expenses in 2018

Read More

USAntibiotics Reopens Facility and Returns Antibiotic Production to the United States from China

USAntibiotics is the Only U.S. Manufacturer of Amoxicillin and Can Meet 100 Percent of the Nation's Demand

Read More

TRISTAR CENTENNIAL MEDICAL CENTER INTRODUCES TWO NEW VICE PRESIDENTS TO ITS SENIOR LEADERSHIP TEAM

TRISTAR CENTENNIAL MEDICAL CENTER INTRODUCES TWO NEW VICE PRESIDENTS TO ITS SENIOR LEADERSHIP TEAM

TriStar Centennial Medical Center is pleased to welcome Laura Godel as the hospital's new Vice President of Oncology Services, and Tyler Rhoden as its new Vice President of Orthopedics, Neurosciences, and Spine.

Read More

ZOOM NAMES MUSICIANS ON CALL SECOND PLACE OVERALL WINNER IN GLOBAL INNOVATION AWARDS

Nashville-based nonprofit honored in annual awards program for innovative use of the platform in delivering the healing power of music to hospitals during the pandemic

Read More

President Biden appoints Karen Winkfield to National Cancer Advisory Board

President Joe Biden has appointed Karen Winkfield, MD, PhD, to the National Cancer Advisory Board, where she will serve a six-year term and help guide federal initiatives that focus on cancer.

Read More

HCA HEALTHCARE NAMES SAMMIE MOSIER CHIEF NURSE EXECUTIVE; JANE ENGLEBRIGHT TO RETIRE AFTER NEARLY 30 YEARS OF SERVICE

HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, announced that Sammie Mosier will assume the role of senior vice president, chief nurse executive, effective December 1, 2021.

Read More

AHA RECEIVES $1 MILLION CDC GRANT TO CONTINUE VACCINE INITIATIVES

The American Hospital Association (AHA) announced today that the organization received $1 million in grant funding from the Centers for Disease Control and Prevention (CDC) to continue COVID-19 vaccine confidence efforts through September 2022.

Read More

Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals

Melt Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021

Read More

Franklin Dental Care to Host Free Dentistry Day Friday, October 1

Residents in the Franklin community and surrounding areas will have the opportunity to receive free dental services at Franklin Dental Care on Friday, October 1.

Read More

Family & Children's Service Awarded $8M to Support ACA Outreach and Enrollment

Family & Children's Service Awarded $8M to Support ACA Outreach and Enrollment

Nashville-Based Nonprofit Awarded Largest Federal Grant in its History

Read More

Edson James Andrews, Jr., M.D., F.A.C.R., F.A.C.C Obituary

Read More

Rheumatoid Arthritis Drug Combined with Standard of Care May Help Reduce Mortality for Hospitalized COVID-19 Patients

Rheumatoid Arthritis Drug Combined with Standard of Care May Help Reduce Mortality for Hospitalized COVID-19 Patients

Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.

Read More

Help tackle the need by giving blood or platelets with the Red Cross

Help tackle the need by giving blood or platelets with the Red Cross

Red Cross and Sport Clips Haircuts partner to offer free haircut coupon to donors in September

Read More

SNAP benefit set to increase providing more dollars for low-income families to spend on food when pandemic relief expires

The Tennessee Justice Center applauds USDA for its reevaluation and cost adjustment of the Thrifty Food Plan, a measure that is used to calculate the monthly Supplemental Nutrition Assistance Program (SNAP) benefit allotment.

Read More

Gen Cap America Partners with Management to Acquire Lab Products

Gen Cap America, Inc. ("Gen Cap"), a private equity firm focused on lower middle market buyouts, announced that, in partnership with management, it has acquired Lab Products, LLC and Harford Systems, LLC (together, "Lab Products") from Avidity Science, LLC. Terms of the transaction were not disclosed.

Read More

New Podcast Provides Entertaining, Enlightening Glimpse into Lives of Area Seniors

New Podcast Provides Entertaining, Enlightening Glimpse into Lives of Area Seniors

In collaboration with Blakeford Senior Life, Ben Oddo is releasing a podcast series this Thursday, September 2, titled Me and All My Friends.

Read More

 
 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: